Craneware (CRW) Share Price, News & Analysis

Company Overview

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.

Key Stats

• Today's Range: 2,180 to 2,215
• 50-Day Range: 1,700 to 2,380
• 52-Week Range: 1,670 to 2,509.20
• Volume: 83,246 shs
• Average Volume: 85,642 shs
• Market Capitalization: £782.78 million
• P/E Ratio: 8,519.23
• Dividend Yield: 1.31%
• Price Target: GBX 2,700
• Consensus Rating: Buy

Craneware Stock Analysis - MarketRank™

Craneware scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Craneware has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Craneware has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Craneware is 8,519.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 112.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Craneware is 8,519.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.11.

Price to Book Value per Share Ratio

Craneware has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRW.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Craneware pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Craneware does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Craneware is 11,153.85%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRW.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Craneware has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Craneware this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Craneware insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.28% of the stock of Craneware is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.17% of the stock of Craneware is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRW Stock Analysis - Frequently Asked Questions

How have CRW shares performed this year?

Craneware's stock was trading at GBX 1,750 on January 1st, 2024. Since then, CRW shares have increased by 26.6% and is now trading at GBX 2,215.
View the best growth stocks for 2024 here.

How do I buy shares of Craneware?

Shares of CRW stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Craneware own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Craneware investors own include Rolls-Royce Holdings plc (RR.L), accesso Technology Group (ACSO), Greencore Group (GNC), Nikola (NKLA), ASOS (ASC), Babcock International Group (BAB) and ChargePoint (CHPT).

Company Calendar

• Ex-Dividend for 12/18 Dividend: 11/28/2024
• Dividend Payable: 12/18/2024
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:CRW
• CUSIP: N/A
• CIK: N/A
• Web: public.craneware.com
• Phone: +44-131-5503100
• Fax: N/A
• Employees: 734
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 2,700
• High Stock Price Target: GBX 2,700
• Low Stock Price Target: GBX 2,700
• Potential Upside/Downside: +21.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.26
• Trailing P/E Ratio: 8,519.23
• Forward P/E Ratio: 28.19
• P/E Growth: N/A
• Net Income: £11.70 million
• Net Margins: 6.18%
• Pretax Margin: N/A
• Return on Equity: 3.57%
• Return on Assets: 2.28%

Debt

• Debt-to-Equity Ratio: 12.22
• Current Ratio: 0.63
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: £189.27 million
• Price / Sales: 4.14
• Cash Flow: GBX 150.51 per share
• Price / Cash Flow: 14.72
• Book Value: GBX 941 per share
• Price / Book: 2.35

Miscellaneous

• Outstanding Shares: 35,340,000
• Free Float: N/A
• Market Cap: £782.78 million
• Optionable: Not Optionable
• Beta: 0.28